{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:37:48Z","timestamp":1760027868045},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12471-018-1112-6","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T10:21:55Z","timestamp":1524478915000},"page":"296-310","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimal pharmacological therapy in ST-elevation myocardial infarction\u2014a\u00a0review"],"prefix":"10.1007","volume":"26","author":[{"given":"R. S.","family":"Hermanides","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"1112_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Yancy CW, et\u00a0al. 2013 ACCF\/AHA guideline for the management of ST elevation myocardial infarction: a\u00a0report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J\u00a0Am Coll Cardiol. 2013;61:485\u2013510.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1161\/CIR.0b013e31823ba622","volume":"124","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Ting HH, et\u00a0al. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:574\u2013651.","journal-title":"Circulation"},{"key":"1112_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James SK, Widimsk\u00fd P, et\u00a0al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart\u00a0J. 2017; https:\/\/doi.org\/10.1093\/eurheartj\/ehx393 .","journal-title":"Eur Heart J"},{"key":"1112_CR4","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker S, Kolh P, Witkowski A, et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart\u00a0J. 2014;35:2541\u2013619.","journal-title":"Eur Heart J"},{"key":"1112_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Dav\u00ec","year":"2007","unstructured":"Dav\u00ec G, Patrono C. Platelet activation and atherothrombosis. N\u00a0Engl J Med. 2007;357:2482\u201394.","journal-title":"N Engl J Med"},{"key":"1112_CR6","doi-asserted-by":"publisher","first-page":"24S","DOI":"10.1378\/chest.11-2291","volume":"141","author":"DA Garcia","year":"2012","unstructured":"Garcia DA, Baglin TP, Samama MM, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:24S\u201343S.","journal-title":"Chest"},{"key":"1112_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","volume":"378","author":"G Montalescot","year":"2011","unstructured":"Montalescot G, Zeymer U, Vicaut E, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378:693\u2013703.","journal-title":"Lancet"},{"key":"1112_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Fox KA, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519\u201330.","journal-title":"JAMA"},{"key":"1112_CR9","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","volume":"358","author":"GW Stone","year":"2008","unstructured":"Stone GW, Witzenbichler B, Mehran R, et\u00a0al. Bivalirudin during primary PCI in acute myocardial infarction. N\u00a0Engl J Med. 2008;358:2218\u201330.","journal-title":"N Engl J Med"},{"key":"1112_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, Lansky AJ, Stone G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1\u2011year results of a\u00a0randomised controlled trial. Lancet. 2009;374:1149\u201359.","journal-title":"Lancet"},{"key":"1112_CR11","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","volume":"377","author":"GW Stone","year":"2011","unstructured":"Stone GW, Witzenbichler B, Mehran R, et al. HORIZONS-AMI Trial Investigators. Heparin plus a\u00a0glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3\u2011year results from a\u00a0multicentre, randomised controlled trial. Lancet. 2011;377:2193\u2013204.","journal-title":"Lancet"},{"key":"1112_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","volume":"369","author":"PG Steg","year":"2013","unstructured":"Steg PG, van \u2019t Hof AWJ, Goldstein P, et\u00a0al. Bivalirudin started during emergency transport for primary PCI. N\u00a0Engl J Med. 2013;369:2207\u201317.","journal-title":"N Engl J Med"},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","volume":"65","author":"GW Stone","year":"2015","unstructured":"Stone GW, Mehran R, Steg PG, et al. Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J\u00a0Am Coll Cardiol. 2015;65:27\u201338.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR14","doi-asserted-by":"publisher","first-page":"i4935","DOI":"10.1136\/bmj.i4935","volume":"354","author":"S Leonardi","year":"2016","unstructured":"Leonardi S, Frigoli E, Windecker S, et\u00a0al. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ. 2016;354:i4935.","journal-title":"BMJ"},{"key":"1112_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamacardio.2016.5975","volume":"2","author":"E Fabris","year":"2017","unstructured":"Fabris E, Kilic S, van \u2019t Hof AWJ, et al. One-year mortality for bivalirudin vs heparin plus optional glycoprotein IIb\/IIIa inhibitor treatment started in the ambulance for ST-segment elevation myocardial infarction: a\u00a0secondary analysis of the EUROMAX randomized clinical trial. JAMA Cardiol. 2017;2:791\u20136.","journal-title":"JAMA Cardiol."},{"key":"1112_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, James S, et\u00a0al. Bivalirudin versus Heparin monotherapy in myocardial infarction. N\u00a0Engl J Med. 2017;377:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1112_CR17","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodr\u00edguez G, Baigent C, et al. Low-dose aspirin for the prevention of atherothrombosis. N\u00a0Engl J Med. 2005;353:2373\u201383.","journal-title":"N Engl J Med"},{"key":"1112_CR18","doi-asserted-by":"crossref","unstructured":"ISIS-2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349\u201360.","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"1112_CR19","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Zanchetti A, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","journal-title":"Lancet"},{"key":"1112_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","volume":"376","author":"SR Mehta","year":"2010","unstructured":"Mehta SR, Tanquay JF, Yusuf S, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a\u00a0randomised factorial trial. Lancet. 2010;376:1233\u201343.","journal-title":"Lancet"},{"key":"1112_CR21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"M Gent","year":"1996","unstructured":"Gent M, Beaumont D, Messa LG, et\u00a0al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329\u201339.","journal-title":"Lancet"},{"key":"1112_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N\u00a0Engl J Med. 2001;345:494\u2013502.","journal-title":"N Engl J Med"},{"key":"1112_CR23","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Costa MA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J\u00a0Am Coll Cardiol. 2007;49:1505\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ahj.2014.03.006","volume":"168","author":"TO Bergmeijer","year":"2014","unstructured":"Bergmeijer TO, Janssen PW, ten Berg JM, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart\u00a0J. 2014;168:16\u201322.","journal-title":"Am Heart J"},{"key":"1112_CR25","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Braunwald E, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923\u201332.","journal-title":"Circulation"},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Antman EM, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723\u201331.","journal-title":"Lancet"},{"key":"1112_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Harrington RA, et\u00a0al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N\u00a0Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"1112_CR28","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","volume":"37","author":"A Sahl\u00e9n","year":"2016","unstructured":"Sahl\u00e9n A, Varenhorst C, Jernberg T, et\u00a0al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart\u00a0J. 2016;37:3335\u201342.","journal-title":"Eur Heart J"},{"key":"1112_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ehjcvp\/pvv034","volume":"2","author":"A Sahl\u00e9n","year":"2016","unstructured":"Sahl\u00e9n A, Varenhorst C, Jernberg T, et al. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish web system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). Eur Heart J Cardiovasc Pharmacother. 2016;2:5\u201312.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1112_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","volume":"371","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, van \u2019t Hof AWJ, Hamm CW, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N\u00a0Engl J Med. 2014;371:1016\u201327.","journal-title":"N Engl J Med"},{"key":"1112_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/2048872617727722","author":"E Fabris","year":"2017","unstructured":"ATLANTIC investigators, Fabris E, van \u2019t Hof AWJ, Montalescot G, et\u00a0al. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. Eur Heart J Acute Cardiovasc Care. 2017; https:\/\/doi.org\/10.1177\/2048872617727722 .","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"10","key":"1112_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.4244\/EIJ-D-17-00634","volume":"13","author":"P Zocca","year":"2017","unstructured":"Zocca P, Liefke C, von Birgelen C, et al. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT. EuroIntervention. 2017;13(10):1168\u201376.","journal-title":"EuroIntervention"},{"key":"1112_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx175","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Deharo P, Bonnet JL, et\u00a0al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart\u00a0J. 2017; https:\/\/doi.org\/10.1093\/eurheartj\/ehx175 .","journal-title":"Eur Heart J"},{"key":"1112_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijcard.2010.08.035","volume":"150","author":"G Biondi-Zoccai","year":"2011","unstructured":"Biondi-Zoccai G, Lotrionte M, Sheiban I, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011;150:325\u201331.","journal-title":"Int J Cardiol"},{"key":"1112_CR35","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg PG, Bhatt DL, Harrington RA, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a\u00a0pooled analysis of patient-level data. Lancet. 2013;382:1981\u201392.","journal-title":"Lancet"},{"key":"1112_CR36","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","volume":"293","author":"G Luca De","year":"2005","unstructured":"De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a\u00a0meta-analysis of randomized trials. JAMA. 2005;293:1759\u201365.","journal-title":"JAMA"},{"key":"1112_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"M Valgimigli","year":"2012","unstructured":"FABOLUS PRO Investigators, Valgimigli M, Tebaldi M, Ferrari R, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5:268\u201377.","journal-title":"JACC Cardiovasc Interv"},{"key":"1112_CR38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-015-0425-7","volume":"75","author":"G Luca De","year":"2015","unstructured":"De Luca G, Savonitto S, Suryapranata H, et al. Platelet GP IIb-IIIa receptor antagonists in primary angioplasty: back to the future. Drugs. 2015;75:1229\u201353.","journal-title":"Drugs"},{"key":"1112_CR39","first-page":"173","volume":"6","author":"S Savonitto","year":"2017","unstructured":"Savonitto S, De Luca G, Bolognese L, et\u00a0al. Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. Eur Heart J: Acute Cardiovasc Care. 2017;6:173\u201390.","journal-title":"Eur Heart J: Acute Cardiovasc Care"},{"key":"1112_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","volume":"372","author":"AWJ \u2019t Hof van","year":"2008","unstructured":"van \u2019t Hof AWJ, ten Berg J, Hamm C, et al. Prehospital initiation of tirofiban in patients with ST elevation myocardial infarction undergoing primary angioplasty (On TIME 2): a\u00a0multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537\u201346.","journal-title":"Lancet"},{"key":"1112_CR41","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","volume":"55","author":"JM Berg ten","year":"2010","unstructured":"ten Berg JM, van \u2019t Hof AWJ, Hamm C, et al. On behalf of the Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Effect of early, pre-hospital initiation of high-bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short and long-term clinical outcome. J\u00a0Am Coll Cardiol. 2010;55:2446\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR42","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1111\/j.1538-7836.2009.03573.x","volume":"7","author":"AA Heestermans","year":"2009","unstructured":"Heestermans AA, Van Werkum JW, van \u2019t Hof AWJ, et al. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. J\u00a0Thromb Haemost. 2009;7:1612\u20138.","journal-title":"J Thromb Haemost"},{"key":"1112_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/ccd.23165","volume":"79","author":"RS Hermanides","year":"2012","unstructured":"Hermanides RS, van Werkum JW, van \u2019t Hof AWJ, et al. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI. Catheter Cardiovasc Interv. 2012;79:956\u201364.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1112_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/hrt.2010.194951","volume":"97","author":"RS Hermanides","year":"2011","unstructured":"Hermanides RS, Heestermans AA, van \u2019t Hof AWJ, et al. High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a\u00a0subgroup analysis of the On-TIME 2 trial. Heart. 2011;97:106\u201311.","journal-title":"Heart"},{"key":"1112_CR45","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1001\/jama.2012.421","volume":"307","author":"GW Stone","year":"2012","unstructured":"Stone GW, Maehara A, Gibson CM, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817\u201326.","journal-title":"JAMA"},{"key":"1112_CR46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","volume":"379","author":"H Thiele","year":"2012","unstructured":"Thiele H, Wohrle J, Schuler G, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a\u00a0randomised trial. Lancet. 2012;379:923\u201331.","journal-title":"Lancet"},{"key":"1112_CR47","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2217\/fca.15.50","volume":"11","author":"F Franchi","year":"2015","unstructured":"Franchi F, Rollini F, Angiolillo DJ, et\u00a0al. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. Future Cardiol. 2015;11:547\u201364.","journal-title":"Future Cardiol"},{"key":"1112_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Mahaffey KW, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N\u00a0Engl J Med. 2012;366:20\u201333.","journal-title":"N Engl J Med"},{"key":"1112_CR49","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","volume":"380","author":"BM Scirica","year":"2012","unstructured":"Scirica BM, Bonaca MP, Morrow DA, et\u00a0al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a\u00a0prespecified subgroup analysis of the TRA 2\u00b0P TIMI 50 trial. Lancet. 2012;380:1317\u201324.","journal-title":"Lancet"},{"key":"1112_CR50","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.jacc.2013.01.066","volume":"61","author":"JL Mega","year":"2013","unstructured":"Mega JL, Braunwald E, Gibson CM, et al. Rivaroxaban in patients stabilized after a\u00a0ST segment elevation myocardial infarction: results from the ATLAS ACS 2 TIMI 51 trial (Anti Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction). J\u00a0Am Coll Cardiol. 2013;61:1853\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR51","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Gibson CM, et al. Clinically significant bleeding with low-dose ribvaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a\u00a0double-blind, multicentre, randomised trial. Lancet. 2017;389:1799\u2013808.","journal-title":"Lancet"},{"key":"1112_CR52","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Fox KA, et\u00a0al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N\u00a0Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"1112_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connoly SJ, Bosch J, et\u00a0al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N\u00a0Engl J Med. 2017; https:\/\/doi.org\/10.1056\/NEJMoa1709118 .","journal-title":"N Engl J Med"},{"key":"1112_CR54","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","volume":"65","author":"G Parodi","year":"2015","unstructured":"Parodi G, Xanthopoulou I, Alexopoulos D, et\u00a0al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J\u00a0Am Coll Cardiol. 2015;65:511\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"1112_CR55","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","volume":"67","author":"F Rollini","year":"2016","unstructured":"Rollini F, Franchi F, Angiolillo DJ, et\u00a0al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention. The CRUSH study. J\u00a0Am Coll Cardiol. 2016;67:1994\u20132004.","journal-title":"J Am Coll Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-018-1112-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-018-1112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-018-1112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T17:54:52Z","timestamp":1571248492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-018-1112-6"}},"subtitle":["A\u00a0review of antithrombotic therapies in STEMI"],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1007\/s12471-018-1112-6","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"23 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.\u00a0Hermanides, S.\u00a0Kilic and A.W.J.\u00a0van\u2019t Hof declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}